Modifiers of risk of hereditary breast and ovarian cancer
Nature reviews. CancerPublished 1 February 2002
Steven A. Narod
Citations176
SJR quartileQ1
SJR score24.38
SNIP11.13
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Hereditary breast and ovarian cancer is among the most commonly encountered adult genetic disease, and it is increasingly important that geneticists, oncologists, surgeons and gynaecologists are aware of the issues regarding risk assessment, prevention and management of women with inherited susceptibility to cancer.
Abstract
Hereditary breast and ovarian cancer is among the most commonly encountered adult genetic disease, and it is increasingly important that geneticists, oncologists, surgeons and gynaecologists are aware of the issues regarding risk assessment, prevention and management of women with inherited susceptibility to cancer. Genetic risk can be modified by external factors, but what are these factors, and how might our knowledge of them help us to better define the risks for individual women and to develop strategies for cancer prevention?
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
JNCI Journal of the National Cancer InstituteTamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
5,508 Citations1998Bernard Fisher, Joseph P. Costantino +15 more
Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
The LancetTamoxifen for early breast cancer: an overview of the randomised trials
4,105 Citations1998Early Breast Cancer Tr.group, -, Klijn, Jan
The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years, and these benefits appeared to be largely irrespective of age, menopausal status, daily tamoxifen dose, and of whether chemotherapy had been given to both groups.
NatureGenome maintenance mechanisms for preventing cancer
3,888 Citations2001Jan H.J. Hoeijmakers
This review summarizes the main DNA caretaking systems and their impact on genome stability and carcinogenesis.
The American Journal of Human GeneticsGenetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
3,047 Citations1998Deborah Ford, Douglas F. Easton +36 more
The lifetime risk of breast cancer appears similar to the risk in BRCA1 carriers, but there was some suggestion of a lower risk in bRCA2 carriers <50 years of age.
New England Journal of MedicineThe Risk of Cancer Associated with Specific Mutations of<i>BRCA1</i>and<i>BRCA2</i>among Ashkenazi Jews
2,262 Citations1997Jeffery P. Struewing, Patricia Hartge +7 more
The risks of breast cancer may be overestimated, but they fall well below previous estimates based on subjects from high-risk families.
PubMedPolychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
2,156 Citations1998C. Focan, S. M. Steinberg +225 more
ScienceAIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
1,659 Citations1997Sarah L. Anzick, Juha Kononen +8 more
Observations identify AIB1 as a nuclear receptor coactivator whose altered expression may contribute to development of steroid-dependent cancers.
PubMedBreast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
1,587 Citations1995Douglas F. Easton, Deborah Ford +1 more
Data from families with evidence of linkage to BRCA1 is used to estimate the age-specific risks of breast and ovarian cancer in BRCa1-mutation carriers and to examine the variation in risk between and within families.
JNCI Journal of the National Cancer InstituteCancer Risks in BRCA2 Mutation Carriers
1,527 Citations1999The Breast Cancer Linkage Consortium
In addition to the large risks of breast and ovarian cancers, BRCA2 mutations may be associated with increased risks of several other cancers.
Nucleic Acids ResearchThe length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
1,176 Citations1994Nancy L. Chamberlain, Erika D. Driver +1 more
It is postulate that this residual AR activity may be sufficient for development of male primary and secondary sex characteristics, but may fall below a threshold level of activity necessary for normal maintenance of motor neuron function.
The American Journal of Human GeneticsPrevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer
992 Citations2001Harvey A. Risch, John R. McLaughlin +11 more
Risks of ovarian, breast, and stomach cancers and leukemias/lymphomas were increased nine-, five-, six- and threefold, respectively, among first-degree relatives of cases carrying BRCA1 mutations, compared with relatives of noncarriers, and risk of colorectal cancer was increased threefold for relatives of Cases carrying B RCA2 mutations.
New England Journal of MedicineBreast Cancer after Prophylactic Bilateral Mastectomy in Women with a<i>BRCA1</i>or<i>BRCA2</i>Mutation
963 Citations2001Hanne Meijers-Heijboer, Bert van Geel +10 more
In women with a BRCa1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up.
The LancetInterim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
886 Citations1998Trevor J. Powles, Rosalind A. Eeles +7 more
The authors have been unable to show any effect of tamoxifen on breast-cancer incidence in healthy women, contrary to the report from the NSABP-P1 study showing a 45% reduction inhealthy women given tamoxIFen versus placebo.
The LancetPrevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women
770 Citations1998Umberto Veronesi, Patrick Maisonneuve +6 more
In this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent and it is essential to continue follow-up to quantify the long-term risks and benefits of tamxifen therapy.
JAMATamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2
765 Citations2001Mary‐Claire King
Tamoxifen reduced breast cancer incidence among healthy BRCA2 carriers by 62%, similar to the reduction in incidence of ER-positive breast cancer among all women in the Breast Cancer Prevention Trial.
JNCI Journal of the National Cancer InstituteBreast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
678 Citations1999Timothy R. Rebbeck, Albert M. Levin +13 more
Bilateral prophylactic oophorectomy is associated with a reduced breast cancer risk in women who carry a BRCA1 mutation, and the likely mechanism is reduction of ovarian hormone exposure.
Pharmacology & TherapeuticsChemopreventive Agents
663 Citations1998Gerald F. Combs, William Gray
According to this two-stage model of the roles of Se in cancer prevention, individuals with nutritionally adequate Se intakes may benefit from Se supplementation and the development of the potential of Se compounds as cancer chemopreventive agents is facilitated.
JAMAA Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer
635 Citations1991Karen Steinberg
To quantify the effect of estrogen replacement therapy on breast cancer risk, a combined dose-response slopes of the relative risk of breast cancer against the duration of estrogen use across 16 studies was combined.
New England Journal of MedicineOral Contraceptives and the Risk of Hereditary Ovarian Cancer
618 Citations1998Steven A. Narod, Harvey A. Risch +11 more
Oral-contraceptive use may reduce the risk of ovarian cancer in women with pathogenic mutations in the BRCA1 or BRCa2 gene, as well as their sisters as controls, in a case-control study.
American Journal of Medical GeneticsUnusual case of Smith‐Lemli‐Opitz syndrome “type II”
588 Citations1995Mary J. Seller, J. A. Russell +1 more
The findings in this fetus extend the wide spectrum of abnormalities of the SLO phenotype, and emphasize that a genetic pathological examination and biochemical studies should always be undertaken on atypical cases, especially fetuses.
Trends in Biochemical SciencesRole of the human RAD51 protein in homologous recombination and double-stranded-break repair
570 Citations1998Peter Baumann, Stephen C. West
The isolation of yeast and human RecA homologues shows that homologous recombination and recombinational repair have been conserved throughout evolution and the goal is now to identify other factors involved in recombinational Repair and to define their roles in this essential process.
The LancetTamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
541 Citations2000Steven A. Narod, Jean-Sébastien Brunet +10 more
Tamoxifen use reduces the risk of contralateral breast cancer in women with pathogenic mutations in the BRCA1 or BRCa2 gene and seems independent of that of oophorectomy.
Proceedings of the National Academy of SciencesThe steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development
536 Citations2000Jianming Xu, Lan Liao +4 more
Mouse SRC-3 is expressed in a tissue-specific fashion and distributed mainly in the oocytes, mammary glands, hippocampus, olfactory bulb, smooth muscle, hepatocytes, and vaginal epithelium, suggesting the diversity among coactivator family members.
Nature GeneticsGermline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation
500 Citations1995Simon A. Gayther, William Warren +14 more
Analysis of families with a history of breast and/or ovarian cancer for germline mutations in BRCA1 suggests a transition in risk such that mutations in the 3′ third of the gene are associated with a lower proportion of ovarian cancer.
ScienceBRCA1 Inhibition of Estrogen Receptor Signaling in Transfected Cells
494 Citations1999Saijun Fan, J.-A. Wang +9 more
It is raised the possibility that wild-type BRCA1 suppresses estrogen-dependent transcriptional pathways related to mammary epithelial cell proliferation and that loss of this ability contributes to tumorigenesis.
The American Journal of Human GeneticsVariation in Cancer Risks, by Mutation Position, in BRCA2 Mutation Carriers
490 Citations2001Deborah J. Thompson, Douglas F. Easton
New England Journal of MedicinePheochromocytomas, Multiple Endocrine Neoplasia Type 2, and von Hippel-Lindau Disease
471 Citations1993Hartmut P.H. Neumann, Dietmar Berger +6 more
All patients with pheochromocytomas should be screened for MEN-2 and von Hippel-Lindau disease to avert further morbidity and mortality in the patients and their families.
JNCI Journal of the National Cancer InstituteRESPONSE: Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
465 Citations1999B. Amirimani, AH Walker +2 more
Journal of Clinical OncologySequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
462 Citations1998T. Frank, Susan Manley +23 more
Analysis of these genes should be considered for women diagnosed with breast cancer who have a high probability of carrying a mutation according to the statistical model developed with these data.
Human GeneticsGenetics of retinoblastoma
438 Citations1979Friedrich Vogel
The genetic basis of retinoblastoma is reviewed and the alternative possibility is suggested that in the nonhereditary variant a single mutational step—possibly a small chromosome aberration—could be enough to produce a tumor.
BioFactorsPreventive effects of drinking green tea on cancer and cardiovascular disease: Epidemiological evidence for multiple targeting prevention
408 Citations2000Kei Nakachi, Satoru Matsuyama +3 more
JNCI Journal of the National Cancer InstitutePrevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer
394 Citations1999Elizabeth Warner, William D. Foulkes +18 more
Genetic testing may be useful when Jewish women with breast cancer are diagnosed before age 50 years or have a close relative with ovarian or early-onset breast cancer.
New England Journal of MedicineParity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a<i>BRCA1</i>or<i>BRCA2</i>Mutation
388 Citations2001Baruch Modan, Patricia Hartge +13 more
The data suggest that it is premature to use oral contraceptives for the chemoprevention of ovarian cancer in carriers of such mutations.
Human GeneticsThe electroencephalogram (EEG) as a research tool in human behavior genetics: Psychological examinations in healthy males with various inherited EEG variants
387 Citations1979F. Vogel, E. Schalt +3 more
The test methods utilized in the main study are expected to demonstrate at the most a small to moderate correlation of the EEGs with psychological phenotypes as defined by test examinations, even if a major part of the genetic variability underlying these phenotypes would be due to differences in brain physiology that could be revealed by EEG variation.
JNCI Journal of the National Cancer InstituteModification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
361 Citations1998Timothy R. Rebbeck, Julie M. Jaffe +3 more
It is determined that a single base change in the 5' flanking region of the CYP3A4 gene was associated with higher clinical stage and grade in men with prostate tumors.
PubMedHaplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.
338 Citations1996Susan L. Neuhausen, Sylvie Mazoyer +23 more
A haplotype of nine polymorphic markers within or immediately flanking the BRCA1 locus in a set of 61 breast/ovarian cancer families selected for having one of six recurrent BRCa1 mutations observed a high degree of haplotype conservation across the region.
The American Journal of Human GeneticsBRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer
320 Citations2000Roxana Moslehi, William Chu +15 more
Only one nonfounder mutation was identified (in this instance, in a woman of mixed ancestry), and the three founding mutations accounted for most of the observed excess risk of ovarian and breast cancer in relatives.
Nature MedicineFrequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
319 Citations1996Patricia N. Tonin, Barbara Weber +26 more
Two founding mutations in BRCa1 and BRCA2 are responsible for a large proportion of Jewish families with the breast-ovarian cancer syndrome.
JAMATubal Ligation, Hysterectomy, and Risk of Ovarian Cancer
314 Citations1993Susan E. Hankinson
It is indicated that tubal ligation, and perhaps hysterectomy, may substantially reduce risk of epithelial ovarian cancer.
PubMedStudy of a single BRCA2 mutation with high carrier frequency in a small population.
299 Citations1997Steinunn Thorlacius, Stefán Sigurðsson +6 more
Comparison of the age at onset for mother/daughter pairs with the 999del5 mutation and breast cancer indicates thatAge at onset is decreasing in the younger generation, and increase in breast cancer incidence and lower age at inception suggest a possible contributing environmental factor.
New England Journal of MedicineAn Association between the Risk of Cancer and Mutations in the HRAS1 Minisatellite Locus
288 Citations1993Theodore G. Krontiris, Bernie Devlin +3 more
The American Journal of Human GeneticsFounder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer
259 Citations2000Bartłomiej Górski, Tomasz Byrski +10 more
The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age <50 years.
The American Journal of Human GeneticsModification of BRCA1-Associated Breast Cancer Risk by the Polymorphic Androgen-Receptor CAG Repeat
256 Citations1999Timothy R. Rebbeck, Philip W. Kantoff +10 more
JAMASerum Gonadotropins and Steroid Hormones and the Development of Ovarian Cancer
254 Citations1995Kathy J. Helzlsouer
The results suggest that women with low serum gonadotropin levels or high androgen levels have an increased risk of ovarian cancer and do not support the hypothesis that pituitary gonadotropic hormone levels increase the risk of Ovarian cancer.
Breast Cancer Research and TreatmentInfluence of age and parity on the development of the human breast
239 Citations1992J. Russo, Rivera Damm R +1 more
It was concluded that there are striking differences in the developmental pattern of the breast between nulliparous and parous women.
The LancetTubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
229 Citations2001Steven A. Narod, Ping Sun +10 more
Tubal ligation is a feasible option to reduce the risk of ovarian cancer in women with BRCA1 mutations who have completed childbearing and no protective effect of tubal ligate was seen among carriers of the BRCa2 mutation.
Journal of Cellular BiochemistryGreen tea extracts decrease carcinogen‐induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture
227 Citations2001Kathryn T. Kavanagh, Laurie J. Hafer +5 more
Green tea had significant chemopreventive effects on carcinogen‐induced mammary tumorigenesis in female S‐D rats, and reduced tumor burden and number of invasive tumors per tumor‐bearing animal.
Gynecologic OncologyA Genetic Epidemiological Study of Carcinoma of the Fallopian Tube
226 Citations2001Samina Aziz, Graciela Kuperstein +5 more
Fallopian tube carcinoma should be considered to be a clinical component of the hereditary breast-ovarian cancer syndrome, and may be associated with BRCA1 and BRCa2 mutations.
The LancetPregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2
224 Citations1999H Jernström, Caryn Lerman +10 more
Whether pregnancy is a risk factor for hereditary breast cancer is established and an early first pregnancy does not confer protection for carriers of BRCA1 or BRCa2 mutations.
JAMARisk of Breast Cancer With Oral Contraceptive Use in Women With a Family History of Breast Cancer
221 Citations2000Dawn M. Grabrick
The results suggest that women who have ever used earlier formulations of OCs and who also have a first-degree relative with breast cancer may be at particularly high risk for breast cancer.
The American Journal of Human GeneticsFrequency and Carrier Risk Associated with Common BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Breast Cancer Patients
220 Citations1998F Fodor, Ainsley Weston +6 more
Presymptomatic screening and counseling for these common mutations in Ashkenazi Jewish women not selected for family history of breast cancer should be reconsidered until the risk associated with these mutations is firmly established, since early diagnostic and preventive-treatment modalities are limited.
Proceedings of the National Academy of SciencesBRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor
213 Citations2001Lei Zheng, Lois A. Annab +3 more
BRCA1 is revealed to be a ligand-reversible barrier to transcriptional activation by unliganded promoter-bound ERα and a possible mechanism by which functional inactivation of BRCA 1 could promote tumorigenesis through inappropriate hormonal regulation of mammary and ovarian epithelial cell proliferation is suggested.
Nature GeneticsOvarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus
203 Citations1996Catherine M. Phelan, Timothy R. Rebbeck +12 more
This study is the first to show the effect of a modifying gene on the penetrance of an inherited cancer syndrome, and whether the presence of rare HRAS1 alleles increases susceptibility to hereditary breast and ovarian cancer.
The Journal of Clinical Endocrinology & MetabolismRelevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.
193 Citations1996Nelson Wohllk, Gilbert J. Cote +8 more
PubMedDoes oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
184 Citations1997Giske Ursin, Brian E. Henderson +5 more
The results suggest that OC use may increase the risk of breast cancer more in mutBRCA carriers than in noncarriers; however, they must be interpreted with caution given the small sample size.
Proceedings of the National Academy of SciencesA single nucleotide polymorphism in the <i>RAD51</i> gene modifies cancer risk in <i>BRCA2</i> but not <i>BRCA1</i> carriers
181 Citations2001Ephrat Levy‐Lahad, Amnon Lahad +9 more
RAD51-135C is a clinically significant modifier of BRCA2 penetrance, specifically in raising breast cancer risk at younger ages, and RAD51 status did not affect ovarian cancer risk.
PubMedInsulin-like growth factors and prostate cancer: a population-based case-control study in China.
172 Citations2001A P Chokkalingam, Michaël Pollak +11 more
Evidence is provided that IGF-I, IGF BP-3, and IGFBP-1 are determinants of prostate cancer and indicate that additional studies are needed to evaluate their effects on ethnic and geographic incidence differentials and to elucidate carcinogenic mechanisms.
PubMedBreast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor.
167 Citations2000John Park, Ryan A. Irvine +7 more
It is suggested that BRCA1 may directly modulate AR signaling and, therefore, may have implications regarding the proliferation of normal and malignant androgen-regulated tissues.
International Journal of CancerRisk modifiers in carriers of brca1 mutations
164 Citations1995Steven A. Narod, David E. Goldgar +6 more
The reproductive histories of 333 North American women found by haplotype analysis to carry BRCAI mutations were studied and it was found that an increased risk for breast cancer was associated with low parity and with recent birth cohort.
PubMedA single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
155 Citations2001W W Wang, Amanda B. Spurdle +18 more
A RAD51 5' untranslated region SNP is identified that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers.
The American Journal of Human GeneticsHaplotype and Phenotype Analysis of Nine Recurrent BRCA2 Mutations in 111 Families: Results of an International Study
151 Citations1998Susan L. Neuhausen, Andrew K. Godwin +28 more
American Journal of EpidemiologyThe Kin-Cohort Study for Estimating Penetrance
144 Citations1998Sholom Wacholder, Patricia Hartge +5 more
The kin-cohort design can be a useful tool for quickly estimating penetrance from volunteers in a setting in which the mutation prevalence is relatively high.
The LancetPregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers
132 Citations1998Oskar T. Johannsson, Niklas Loman +2 more
Europe PMC (PubMed Central)Study of a single BRCA2 mutation with high carrier frequency in a small population.
131 Citations1997Thorlacius, S, Sigurdsson, S +6 more
Human GeneticsThe electroencephalogram (EEG) as a research tool in human behavior genetics: Psychological examinations in healthy males with various inherited EEG variants
123 Citations1979F. Vogel, E. Schalt +1 more
The low-voltage (N) group scored high in intelligence tests, especially in spatial orientation and personality scores revealed this group as ‘normal’, extravert, group-dependent, and not very energetic.
PubMedModification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
119 Citations2001Timothy R. Rebbeck, Yao Lin Wang +12 more
The hypothesis that pathways involving endocrine signaling, as measured through AIB1 genotype and reproductive history, may have a substantial effect on BRCA1/2-associated breast cancer risk is supported.
CarcinogenesisNo association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer
116 Citations1999Alison M. Dunning, Simon McBride +9 more
None of the AR or VDR polymorphisms investigated has a major effect on risk of breast cancer in the British population.
Molecular Genetics and MetabolismGenetic Factors Related to Racial Variation in Plasma Levels of Insulin-Like Growth Factor-1: Implications for Premenopausal Breast Cancer Risk
110 Citations2001Helena Jernström, William Chu +6 more
Polymorphic variants in the CYP3A4, IGF1, and AIB1 genes are associated with increases in the plasma levels of IGF-I among oral contraceptive users and the variant alleles are much more common in black women than in white women.
PubMedShort polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population.
91 Citations2001Yves Giguère, Éric Dewailly +8 more
Differences in the number of polyglutamines in the AR protein may influence individual risk of breast cancer, especially in postmenopausal women, and that this apparent protection could be the consequence of an increased response/sensitivity to androgens.
JNCI Journal of the National Cancer InstituteAndrogen Receptor Exon 1 CAG Repeat Length and Breast Cancer in Women Before Age Forty Years
82 Citations1999Amanda B. Spurdle, Gillian S. Dite +12 more
There was no evidence for an association between AR exon 1 CAGn length and breast cancer risk in women under the age of 40, despite having 80% power to detect modest effects.
Annals of the New York Academy of SciencesMultifunctional Aspects of the Action of Indole‐3‐Carbinol as an Antitumor Agent
81 Citations1999H. Leon Bradlow, Daniel W. Sepkovic +2 more
Indole‐3‐carbinol, a compound found in cruciferous vegetables, and its further metabolites in the body, diindolylmethane (DIM) and indolylcarbazole (ICZ), is focussed on because of its relative safty and multifaceted activities.
The LancetTubal ligation and risk of ovarian cancer
80 Citations2001Jurgen M.J. Piek, P J van Diest +3 more
PubMedThe androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.
76 Citations2001Douglas A. Levine, Julia Boyd
It is suggested that AR allele length affects age of diagnosis of ovarian cancer, irrespective of BRCA mutation status, as well as polymorphic variation in the CAGn repeat of the androgen receptor (AR) gene.
European Journal of Human GeneticsAndrogen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype
41 Citations2002Efrat Dagan, Eitan Friedman +3 more
There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers, but a small effect of a short AR C AG allele size on breast cancer at early age (<42 years) cannot be excluded.
Journal of Bone and Mineral ResearchAlleles of the Estrogen Receptor α-Gene and an Estrogen Receptor Cotranscriptional Activator Gene, Amplified in Breast Cancer-1 (<i>AIB1</i>), Are Associated with Quantitative Calcaneal Ultrasound
39 Citations2000Millan S. Patel, David E.C. Cole +7 more
This is the first demonstration of specific genetic effects on calcaneal QUS encoded by alleles of genes directly involved in mediating estrogen effects on bone.
Breast Cancer ResearchBRCA2 and homologous recombination
33 Citations2001Brian J. Orelli, Douglas K. Bishop
The context in which the two studies were carried out is reviewed, the results presented are commented on, and models designed to account for the role of BRCA2 in RAD51–mediated repair are discussed.
Adelaide Research & Scholarship (AR&S) (University of Adelaide)Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor
24 Citations2000Park, J., Irvine, R. +7 more
Breast Cancer ResearchIncreased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line
19 Citations2000Lois A. Annab, Rebecca Hawkins +3 more
Reduction of BRCA1 protein in BG-1 ovarian adenocarcinoma cells may have an effect on cell survival during estrogen deprivation both in vitro and in vivo, and clonal studies demonstrated that reduced levels of BRA1 protein correlated with growth in soft agar and greater tumor formation in nude mice in the absence of estrogen.
…